Innate Pharma (IPHA) Stock Chart & Stock Price History $2.13 -0.02 (-0.70%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Innate Pharma Stock Price Performance The Innate Pharma (IPHA) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 0.47%, with a year-to-date return of 16.03%. In the past month, the stock has increased 17.24%, reflecting recent market activity. As of the latest close, Innate Pharma traded at $2.15 with a market cap of $198.20 million and volume of 10,387 shares. Five years ago, the stock traded at $6.20, representing a 65.56% decrease over that period. At the time, it had a market cap of $474.55 million and a volume of 867 shares. Receive IPHA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.18%1 Month Performance+17.24%3 Month Performance-5.53%Year-To-Date Performance+16.03%1 Year Performance-0.47%5 Year Performance-65.56% IPHA Stock Chart for Monday, August, 4, 2025 IPHA Chart by TradingView Innate Pharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/01/2025$2.11$2.15+1.90%$2.22$2.1410,387 shs$198.20 million07/31/2025$2.11$2.11$2.30$2.1119,774 shs$194.50 million07/30/2025$2.14$2.11-1.40%$2.63$2.1132,001 shs$194.50 million07/29/2025$2.20$2.14-2.73%$2.34$2.1421,945 shs$197.27 million07/28/2025$2.04$2.20+7.84%$2.36$2.0988,428 shs$202.80 million07/25/2025$2.03$2.04+0.27%$2.08$2.033,493 shs$188.05 million07/24/2025$1.98$2.03+2.80%$2.10$1.948,703 shs$187.55 million07/23/2025$1.89$1.98+4.99%$1.99$1.8810,565 shs$182.44 million07/22/2025$1.87$1.89+1.07%$1.92$1.872,127 shs$173.76 million07/21/2025$1.92$1.87-2.86%$1.92$1.876,814 shs$171.92 million Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 07/18/2025$1.81$1.92+6.37%$1.98$1.8917,431 shs$176.99 million07/17/2025$1.80$1.81+0.28%$1.77$1.752,247 shs$166.39 million07/16/2025$1.77$1.80+1.69%$1.84$1.744,349 shs$165.92 million07/15/2025$1.70$1.77+4.12%$1.77$1.713,871 shs$163.16 million07/14/2025$1.74$1.70-2.48%$1.75$1.705,697 shs$156.71 million07/11/2025$1.81$1.74-3.69%$1.81$1.704,886 shs$160.69 million07/10/2025$1.72$1.81+5.23%$1.81$1.7112,591 shs$166.84 million07/09/2025$1.75$1.72-1.71%$1.75$1.727,208 shs$158.55 million07/08/2025$1.79$1.75-2.23%$1.80$1.755,241 shs$161.32 million07/07/2025$1.82$1.79-1.70%$1.81$1.785,539 shs$165.00 million07/04/2025$1.82$1.82$1.81$1.81204 shs$167.86 million07/03/2025$1.82$1.82+0.05%$1.81$1.81204 shs$167.85 million Related Companies TNGX Stock Price Chart MNMD Stock Price Chart MAZE Stock Price Chart NAGE Stock Price Chart UPB Stock Price Chart DAWN Stock Price Chart KALV Stock Price Chart AMLX Stock Price Chart AVBP Stock Price Chart GYRE Stock Price Chart Receive IPHA Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:IPHA) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
